Clinical Context
A typical patient receiving Q5125 is an adult or pediatric oncology patient with chemotherapy-induced neutropenia or at high risk for neutropenic complications following cytotoxic chemotherapy. The clinical workflow begins with the oncology or hematology team ordering a granulocyte colony-stimulating factor (G-CSF) biosimilar — filgrastim-ayow (releuko) — dosed in micrograms based on body weight. The patient presents to an outpatient oncology infusion center, hospital outpatient department, or physician office for administration. Prior to injection, nursing verifies recent complete blood count (CBC) results, weight-based dose calculation, medication reconciliation, and allergy history. The product is prepared under aseptic technique, labeled with lot number and expiration, and administered subcutaneously, typically in the abdomen or thigh. Post-injection monitoring is brief; the patient is observed for immediate adverse events such as injection-site reaction, bone pain, or rare hypersensitivity. Documentation includes the biosimilar product name filgrastim-ayow, NDC or lot number, dose in micrograms, route (subcutaneous), site of administration, and any applicable modifier to indicate circumstances (for example, JW for discarded drug when partial vial contents are wasted). Billing uses Q5125 per microgram with supporting clinical documentation and the appropriate ICD-10 diagnosis indicating neutropenia or chemotherapy regimen intent to reduce febrile neutropenia risk. Typical sites of service: outpatient infusion center, hospital outpatient department, physician office, and occasionally home health when administered by qualified nursing staff.